Introduction
Background
Respiratory distress syndrome (RDS) of the newborn is an acute lung disease of the newborn caused by surfactant deficiency. It is seen primarily in neonates younger than 36-38 weeks' gestational age and weighing less than 2500 g. In comparison, hyaline membrane disease (HMD) tends to occur in neonates younger than 32 weeks' gestational age and weighing less than 1200 g.
Classic respiratory distress syndrome (RDS). Bell-shaped thorax is due to generalized underaeration. Lung volume is reduced, the lung parenchyma has a diffused reticulogranular pattern, and peripherally extending air bronchograms are present.
Moderately severe respiratory distress syndrome (RDS). The reticulogranular pattern is more prominent and uniformly distributed than usual. The lungs are hypoaerated. Increased air bronchograms are observed.
Severe respiratory distress syndrome (RDS). Reticulogranular opacities are present throughout both lungs, with prominent air bronchograms and total obscuration of the cardiac silhouette. Cystic areas in the right lung may represent dilated alveoli or early pulmonary interstitial emphysema (PIE).
The incidence and severity of RDS is inversely related to gestational age. RDS is the most common cause of respiratory failure during the first days after birth. In addition to prematurity, other factors contributing to the development of RDS are maternal diabetes, cesarean delivery without preceding labor,1 fetal asphyxia, and being the second born of twins.
The outcome of patients with RDS has improved with the increased use of antenatal steroids to improve pulmonary maturity, early postnatal surfactant therapy to replace surfactant deficiency, and gentle techniques of ventilation to reduce barotrauma to the immature lungs.
Randomized, controlled trials have shown surfactant therapy to be efficacious in treating infants with, or at risk for, respiratory distress syndrome. One study by Soll et al demonstrated that multiple doses of animal-derived surfactant extract provide greater improvement than single-dose therapy regarding oxygenation and ventilatory requirements, reduced risk of pneumothorax, and improved survival.2
Lahra et al found that maternal and fetal intrauterine inflammatory responses (chorioamnionitis and umbilical vasculitis) are protective for RDS. In this study, chorioamnionitis with umbilical vasculitis was found to provide a markedly greater reduction of RDS than the presence of chorioamnionitis alone.3
Pathophysiology
Respiratory distress syndrome (RDS; hyaline membrane disease) is the result of anatomic pulmonary immaturity and a deficiency of surfactant. Pulmonary surfactant synthesis, in type II pneumocytes, begins at 24-28 weeks of gestation and gradually increases until full gestation. Pulmonary surfactant decreases surface tension in the alveolus during expiration, allowing the alveolus to remain partly expanded, thereby maintaining a functional residual capacity.4,5
In premature infants, an absence of surfactant results in poor pulmonary compliance, atelectasis, decreased gas exchange, and severe hypoxia and acidosis. Premature infants must expend a great deal of effort to expand their lungs with each breath, and respiratory failure ensues.
The lack of surfactant and the resultant poor compliance of the lungs causes debris consisting of damaged or desquamated cells, exudative necrosis, and leaked protein, which lines the alveolar sacs. On hematoxylin-eosin staining, this lining stains like hyaline cartilage.
Hyaline membrane disease (HMD) was originally named for these hyaline membranes, but their presence is not specific for the disease. These hyaline membranes can be seen with other conditions, such as meconium aspiration, bronchopulmonary dysplasia (BPD), and neonatal pneumonia. In addition, hyaline membranes are frequently absent in infants with RDS who die at less than 4 hours of age. (Approximately 4 hours of breathing are usually required for pathologically identifiable hyaline membranes to form.) The disparity between the clinical and pathologic findings has led to use of the term respiratory distress syndrome, or RDS, instead of hyaline membrane disease, or HMD.
Hyaline membranes may form in response to pulmonary hemorrhage; pulmonary edema; and various irritants to the terminal airways, alveolar sacs, and alveoli.
Intrauterine stress may cause an outpouring of endogenous steroids, which cause the type 2 alveolar-lining cells to mature and produce surfactant. This steroid output also causes the thymus to shrink, as thymic atrophy can be induced by corticosteroids or corticotropin. Therefore, a premature neonate with no thymus is less likely than other neonates to have RDS.
Frequency
United States
Respiratory distress syndrome (RDS; hyaline membrane disease) occurs in approximately 40,000 infants each year (1-2% of newborn infants or in 14% of infants weighing less than 2500 g).
The incidence of RDS increases from 5% at 35-36 weeks to 65% at 29-30 weeks of gestation. The incidence of RDS is altered by antenatal maternal glucocorticoid use, as follows:
- For infants born earlier than 30 weeks of gestation, rates are 60% without glucocorticoid therapy versus 35% with antenatal glucocorticoid therapy.
- For infants born between 30 and 34 weeks of gestation, rates are 25% without glucocorticoid therapy versus 10% with antenatal glucocorticoid therapy.
- For infants born after 34 weeks of gestation, the overall incidence is about 5%.
International
Respiratory distress syndrome (RDS; hyaline membrane disease) is reported worldwide in premature infants of all races.6
Mortality/Morbidity
Respiratory distress syndrome (RDS; hyaline membrane disease) is a leading cause of mortality in infants and accounts for 20% of all neonatal deaths.
- Mortality rates have dramatically decreased in infants with RDS with the use of continuous positive-pressure ventilation with end-expiratory positive pressure and surfactant replacement therapy.
- Mortality rates associated with HMD are less than 10% for neonates older than 28 weeks' gestation.
- The major long-term sequela is the development of chronic lung disease, which is defined as the need for oxygen or ventilation after 1 month of age. This complication occurs in 20% of survivors of RDS. As many as 10% of infants who develop chronic lung disease die in the first 2 years of life because of respiratory failure, pulmonary infection, or sudden death.
Race
White infants are more commonly affected than black infants
Sex
Respiratory distress syndrome (RDS; hyaline membrane disease) is twice as common in boys as in girls at every gestational age.
Age
Respiratory distress syndrome (RDS; hyaline membrane disease) predominantly occurs in infants younger than 32 weeks' gestational age and in those weighing less than 1200 g.
- RDS frequently occurs in infants born to mothers with diabetes, in infants born by means of cesarean delivery without maternal labor, in the second born of twins, and in infants with a family history of RDS.
- Secondary surfactant deficiency may occur in infants with intrapartum asphyxia, pulmonary infections, pulmonary hemorrhage, meconium aspiration pneumonia, and oxygen toxicity to the lungs.7
- The use of antenatal steroids or conditions that induce prepartum stress and thus increase production of maternal steroids and accelerate surfactant production can prevent RDS. Examples of these conditions are pregnancy-induced or chronic maternal hypertension, prolonged rupture of membranes, and maternal narcotic addiction.8
Presentation
Infants with respiratory distress syndrome (RDS; hyaline membrane disease) have all of the clinical signs of respiratory distress. The clinical presentation of expiratory grunting (due to partial closure of glottis), tachypnea, subcostal and intercostals retractions, nasal flaring, and cyanosis usually manifests in the first few hours and almost always before 8 hours of age. If symptoms do not develop until after 8 hours of normal breathing, RDS is excluded. On auscultation, air movement is diminished despite vigorous respiratory effort.
Cyanosis and hypoxia frequently become severe. Tachypnea, with respiratory rate greater than 60 breaths per minute, develops early. Functional residual capacity and pulmonary compliance are greatly reduced. Cyanosis, apnea, and circulatory collapse are grave clinical prognostic indicators. A mixed respiratory and metabolic acidosis usually develops. Arterial blood gas studies show hypoxemia, hypercapnia, and respiratory acidosis. Hypoglycemia, hyperkalemia, and hypocalcemia are also common.
Increased pulmonary vascular resistance develops because of a noncompliant lung, hypoxia, and acidosis. This effect increases the right-to-left shunt through a patent ductus arteriosus (PDA). Perfusion of atelectatic air spaces and uneven distribution of inspired air result in a ventilation-perfusion mismatch that initiates a chain of physiologic events that accounts for most of the findings in RDS. Death often directly results from pulmonary disease. However, it may also result from complications related to hypoxemia (eg, intracranial hemorrhage, disseminated intravascular coagulation [DIC], pulmonary hemorrhage, congestive heart failure [CHF] due to left-to-right shunting through PDA), or air blockage complications of assisted ventilation (eg, pulmonary interstitial emphysema [PIE], pneumothorax, pneumomediastinum, gas embolism).
Complication of respiratory distress syndrome (RDS). After receiving ventilation therapy, this premature infant with RDS developed pulmonary interstitial emphysema (PIE) with discrete linear and cystic radiolucent air collections throughout the right lung.
Complication of respiratory distress syndrome (RDS). Anteroposterior (AP) chest radiograph in a neonate with RDS shows a right tension pneumothorax with herniation of right upper lung across midline. Pneumomediastinum is also present.
Complication of ventilation therapy. Bronchopulmonary dysplasia. Anteroposterior (AP) chest radiograph in a 4-week-old premature infant with history of respiratory distress syndrome (RDS) and receiving mechanical ventilation shows moderate pulmonary hyperinflation, coarse interstitial opacities with a honeycomb appearance throughout both lungs, and atelectasis in the right upper lobe.
The symptoms of RDS usually peak by the third day, and they may resolve quickly when diuresis starts and when infants begin to need less oxygen and mechanical ventilation. Clinical improvement is accompanied by a rapid fall in pulmonary vascular resistance and a rise in systemic arterial pressure, which sometimes leads to the development of a large left-to-right shunt through a PDA. Therefore, the patient's recovery may be interrupted by the development of CHF and pulmonary edema.
In RDS, symptoms appear shortly after birth and always within first 8 hours of life. Respiratory symptoms starting after 8 hours of age are unlikely to be the result of RDS. Findings include dyspnea, inspiratory retractions, tachypnea, nasal flaring, expiratory grunting, and progressive cyanosis. Subxiphoid retraction reflects decrease lung volume. In fetal aspiration syndrome, transient tachypnea of the newborn (TTN), and neonatal pneumonia, clinical symptoms appear in 12-24 hours, within 6 hours, and in less than 6 hours, respectively. In addition, lung volumes are usually increased in these conditions. The absence of cyanosis excludes congenital pulmonary lymphangiectasis as a diagnosis.
In infants not receiving assisted ventilation, clinical improvement is associated with the slow clearing of the lungs and a patchy return of normal alveolar aeration. No residual changes are observed, and postrecovery pulmonary function is normal. In contrast, in infants of RDS who receive assisted ventilation, residual pulmonary changes are common and referred to as bronchopulmonary disease (BPD).
Preferred Examination
Respiratory distress syndrome (hyaline membrane disease) is usually diagnosed with a combination of clinical signs and/or symptoms, chest radiographic findings, and arterial blood gas results.
Differential Diagnoses
Meconium Aspiration
Pneumonia, Neonatal
Pulmonary Edema, Noncardiogenic
Transient Tachypnea of the Newborn
Other Problems to Be Considered
Congenital pulmonary alveolar proteinosis
Pulmonary hemorrhage (early)
Sepsis
Pulmonary edema: Problems to consider include PDA, obstruction of pulmonary venous drainage, hypoplastic left heart syndrome, and neurogenic pulmonary edema secondary to intracranial hemorrhage.
Other conditions associated with hypoaeration of the lungs: These include heavy maternal sedation, severe hypoxemia, hypothermia, and CNS damage. The conditions that result in secondary hypoaeration do not cause the diffuse bilateral granular opacities observed with RDS.
More on Hyaline Membrane Disease |
 Overview: Hyaline Membrane Disease |
| Imaging: Hyaline Membrane Disease |
| Follow-up: Hyaline Membrane Disease |
| Multimedia: Hyaline Membrane Disease |
| References |
| Further Reading |
| Next Page » |
References
[Best Evidence] Malloy MH. Impact of cesarean section on intermediate and late preterm births: United States, 2000-2003. Birth. Mar 2009;36(1):26-33. [Medline].
[Best Evidence] Soll R, Ozek E. Multiple versus single doses of exogenous surfactant for the prevention or treatment of neonatal respiratory distress syndrome. Cochrane Database Syst Rev. Jan 21 2009;CD000141. [Medline].
[Best Evidence] Lahra MM, Beeby PJ, Jeffery HE. Maternal versus fetal inflammation and respiratory distress syndrome: a 10-year hospital cohort study. Arch Dis Child Fetal Neonatal Ed. Jan 2009;94(1):F13-6. [Medline].
De Luca D, Baroni S, Vento G, Piastra M, Pietrini D, Romitelli F, et al. Secretory phospholipase A2 and neonatal respiratory distress: pilot study on broncho-alveolar lavage. Intensive Care Med. Oct 2008;34(10):1858-64. [Medline].
Cherif A, Ben jemaa W, Kacem S, Guellouze N, Jebnoun S, Khrouf N. [Preeclampsia increases the risk of hyaline membrane disease in premature infant: a retrospective controlled study]. J Gynecol Obstet Biol Reprod (Paris). Oct 2008;37(6):597-601. [Medline].
Ersch J, Roth-Kleiner M, Baeckert P, Bucher HU. Increasing incidence of respiratory distress in neonates. Acta Paediatr. Nov 2007;96(11):1577-81. [Medline].
Teksam O, Kale G. The effects of surfactant and antenatal corticosteroid treatment on the pulmonary pathology of preterm infants with respiratory distress syndrome. Pathol Res Pract. 2009;205(1):35-41. [Medline].
Pole JD, Mustard CA, To T, Beyene J, Allen AC. Antenatal steroid therapy for fetal lung maturation: is there an association with childhood asthma?. J Asthma. Feb 2009;46(1):47-52. [Medline].
Chernick V, Kendig EL. Kendig's Disorders of the Respiratory Tract in Children, 5th ed. WB Saunders;1990: 274.
Cleveland RH. A radiologic update on medical diseases of the newborn chest. Pediatr Radiol. 1995;25(8):631-7. [Medline].
Cleveland RH, Todres ID. Patterns of evolution of X-ray changes in respiratory distress syndrome. Helv Paediatr Acta. Feb 1981;36(1):43-53. [Medline].
Dinger J, Schwarze R, Rupprecht E. Radiological changes after therapeutic use of surfactant in infants with respiratory distress syndrome. Pediatr Radiol. Jan 1997;27(1):26-31. [Medline].
Gandilo SB, Tanswell AK, Mackie KW. Pulmonary vascular air embolism in hyaline membrane disease. J Can Assoc Radiol. Dec 1977;28(4):294-6. [Medline].
Gortner L, Wauer RR, Hammer H, et al. Early versus late surfactant treatment in preterm infants of 27 to 32 weeks'' gestational age: a multicenter controlled clinical trial. Pediatrics. Nov 1998;102(5):1153-60. [Medline].
Griscom NT, Wheeler WB, Sweezey NB, et al. Bronchopulmonary dysplasia: radiographic appearance in middle childhood. Radiology. Jun 1989;171(3):811-4. [Medline].
Helbich TH, Popow C, Dobner M, et al. New-born infants with severe hyaline membrane disease: radiological evaluation during high frequency oscillatory versus conventional ventilation. Eur J Radiol. Oct 1998;28(3):243-9. [Medline].
Kamper J, Schioeler HU. Chest x-ray changes in survivors of severe idiopathic respiratory distress syndrome. Ann Radiol (Paris). 20(1):95-102. [Medline].
Kattwinkel J, Bloom BT, Delmore P, et al. High-versus low-threshold surfactant retreatment for neonatal respiratory distress syndrome. Pediatrics. Aug 2000;106(2 Pt 1):282-8. [Medline].
Kirks RD, Griscom NT. Practical pediatric imaging. Diagnostic radiology of infants and children. 3rd ed. Philadelphia: Lippincott-Raven;. 1998: 693-708.
Slama M, André C, Huon C, et al. Radiological analysis of hyaline membrane disease after exogenous surfactant treatment. Pediatr Radiol. Jan 1999;29(1):56-60. [Medline].
Slovis TL, Shankaran S. Patent ductus arteriosus in hyaline membrane disease: chest radiography. AJR Am J Roentgenol. Aug 1980;135(2):307-9. [Medline].
Sty JR, Wells RG, Starshak RJ. Diagnostic imaging of infants and children. Vol 3. Maryland: Aspen Publisher Inc;. 1992:123-132.
Swischuk LE. Bubbles in hyaline membrane disease. Differentiation of three types. Radiology. Feb 1977;122(2):417-26. [Medline].
Swischuk LE. Imaging of The Newborn, Infants and Young Child. Vol 1. Baltimore: Williams & Wilkins;. 1989: 28-49.
Taylor GA, Short BL, Kriesmer P. Extracorporeal membrane oxygenation: radiographic appearance of the neonatal chest. AJR Am J Roentgenol. Jun 1986;146(6):1257-60. [Medline].
Truog WE, Jackson JC, Standaert TA, et al. Acute changes in vasoactive lipid mediators in experimental hyaline membrane disease. Respir Physiol. Dec 1992;90(3):363-75. [Medline].
Weller MH. The roentgenographic course and complications of hyaline membrane disease. Pediatr Clin North Am. May 1973;20(2):381-406. [Medline].
Wohlfeld GM. Hyaline membrane disease. Am J Roentgenol Radium Ther Nucl Med. Feb 1965;93:425-7. [Medline].
Wolfson SL, Frech R, Hewitt C, Shanklin DR. Radiographic diagnosis of hyaline membrane disease. Radiology. Aug 1969;93(2):339-43. [Medline].
Further Reading
Clinical guidelines
Antenatal corticosteroids to prevent respiratory distress syndrome.
Royal College of Obstetricians and Gynaecologists - Medical Specialty Society. 1996 Apr (revised 2004 Feb). 9 pages. NGC:004470
Fetal lung maturity.
American College of Obstetricians and Gynecologists - Medical Specialty Society. 2008 Sep. 10 pages. NGC:006763
Clinical trials
Antenatal Corticoid Therapy for Late Preterm Babies
Genetic Regulation of Surfactant Deficiency
Nasal Intermittent Positive Pressure Ventilation in Premature Infants
Related eMedicine topics
Respiratory Distress Syndrome
Multiple Births
Pediatrics, Respiratory Distress Syndrome
Premature Rupture of Membranes
Preterm Labor
Keywords
hyaline membrane disease, HMD, respiratory distress syndrome, RDS, infant respiratory distress syndrome, IRDS, pulmonary disease of immaturity, neonatal respiratory failure, neonatal respiratory distress syndrome, maternal diabetes, cesarean delivery without labor, fetal asphyxia, second born of twins, antenatal steroids, surfactant therapy, pulmonary surfactants, pulmonary alveoli, pulmonary atelectasis
